- Filed
- Feb 12, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Eli Lilly's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Sales through the LillyDirect digital healthcare platform are a growing part of the business, and the company is actively exploring new partnerships and tools to expand it.
digital health care platform
High revenue concentration with three wholesalers: McKesson, Cencora, and Cardinal Health.
A significant percentage of Lilly's consolidated revenue is dependent on three wholesale distributors: McKesson, Cencora, and Cardinal Health.
McKesson CorporationCencora, Inc.Cardinal Health, Inc.
The company is growing its direct-to-patient platform, LillyDirect, creating a new sales channel and reducing reliance on its three main wholesale distributors.
McKesson CorporationCencora, Inc.Cardinal Health, Inc.
New digital initiatives are exacerbating IT system inadequacy and cybersecurity risks.
The company explicitly links new initiatives like its LillyDirect platform to increased risks of IT system failures, security breaches, and data compromises.
Use of AI across operations is creating new regulatory, litigation, and cybersecurity risks.
Lilly is using artificial intelligence in its operations and through third-party partnerships, but acknowledges this exacerbates competitive, regulatory, litigation, and cybersecurity risks.
artificial intelligence
Facing significant risks from the proliferation of counterfeit and illegal versions of its products.
The company identifies the spread of counterfeit, misbranded, or illegally compounded products as a key risk.
Lilly is facing manufacturing disruptions and shortages driven by high variability in demand and its reliance on third-party performance.
Company flags risk of manufacturing shortages due to demand variability and labor shortages.
Lilly is concerned about its ability to maintain product supply due to unpredictable demand, labor issues, and reliance on third parties.
Lilly faces intensifying R&D and market competition from companies in China.
The company explicitly calls out intensifying competition from China, where firms are expanding R&D, licensing products globally, and competing directly in major markets.
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Eli Lilly with the Signal API
One POST /v1/companies/enrich call with lilly.com returns Eli Lilly 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"lilly.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Eli Lilly 10-K
When did Eli Lilly file its latest 10-K?
What does Eli Lilly's latest 10-K say about channel shift?
Where can I find Eli Lilly's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .